Skip to main content
XORTX Therapeutics Inc. logo

XORTX Therapeutics Inc. — Investor Relations & Filings

Ticker · XRTX ISIN · CA98420Q4051 TSXV Manufacturing
Open in API
Filings indexed 235 across all filing types
Latest filing 2026-04-21 Capital/Financing Update
Country CA Canada
Listing TSXV XRTX

About XORTX Therapeutics Inc.

https://www.xortx.com/

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for metabolic and cardiovascular diseases, particularly those involving aberrant purine and uric acid metabolism, such as gout and progressive kidney diseases. The company's pipeline includes four programs, three of which are clinically advanced. The lead candidate, XRx-026, is approaching pre-NDA filing for treating gout patients who are non-responsive to standard allopurinol therapy. Other programs target progressive Autosomal Dominant Polycystic Kidney Disease (XRx-008), acute kidney disease associated with viral infections (XRx-101, a proprietary oxypurinol formulation), and Type 2 Diabetic Nephropathy (XRx-225). XORTX specializes in developing first-in-class uric acid lowering agents and utilizes a precision medicine approach.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that XORTX Therapeutics Inc. has met Nasdaq's continued listing requirements following a reverse stock split. It discusses compliance with Nasdaq Rule 5550(a)(2) regarding minimum bid price and provides company background and forward-looking statements. There is no detailed financial data, no full report, no earnings summary, or management discussion. The document is an update on capital structure compliance and listing status, which fits best under Capital/Financing Update (CAP). The document length is 4601 characters, which is consistent with a brief announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2026-04-21 English
News release - English.pdf
M&A Activity Classification · 92% confidence The document is a corporate press release announcing the closing of an acquisition (the Vectus kidney anti-fibrotic asset) by XORTX Therapeutics. It details the terms of the acquisition, share issuance, and strategic rationale. This falls squarely under M&A Activity (announcements of merger/takeover/acquisition transactions).
2026-04-13 English
News release - English.pdf
Capital/Financing Update Classification · 85% confidence The document is a press release announcing the closing of an acquisition and detailing the equity consideration (common shares and pre-funded warrants) issued to fund the transaction. It is not an annual or interim report, earnings release, management change, or AGM material, nor is it regulatory or a simple publication announcement. The focus is on the capital structure change and financing via share issuance to acquire an asset, which fits the Capital/Financing Update category.
2026-04-13 English
News release - English.pdf
M&A Activity Classification · 90% confidence The document is a press release announcing the closing of an acquisition of Vectus’s kidney anti-fibrotic asset and details the share and warrant consideration issued as part of the transaction. It is not an earnings release, dividend notice, board change, or regulatory form filing, but rather an M&A transaction announcement. Therefore, it falls under M&A Activity (Code: TAR).
2026-04-13 English
News release - English.pdf
Share Issue/Capital Change Classification · 85% confidence The document is a press release announcing the effective date and details of a share consolidation (one new common share for every five old shares). This is a corporate action altering the company’s share capital structure (stock consolidation/reverse split). It does not announce fundraising or financing activities per se, nor is it a regulatory report or dividend notice. It fits the definition for Share Issue/Capital Change (Code: SHA).
2026-04-01 English
News release - English.pdf
Management Reports Classification · 93% confidence The document is a standalone “Management Discussion and Analysis” (MD&A), which is management’s detailed explanation of the company’s financial results, business trends, risks, and outlook for the year ended December 31, 2025. It is not merely an announcement of a report, nor is it a full annual financial statement like a 10-K, nor an interim report. This aligns exactly with category “Management Reports (MDA).”
2026-04-01 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.